-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma (MM) is a malignant plasma cell disease, accounting for about 10% of hematologic malignancies, second only to non-Hodgkin lymphoma, and more likely to occur in middle-aged and elderly people
.
In recent years, with the continuous advent of new drugs and the innovation of treatment methods, MM treatment has been gradually optimized and improved
.
In the previous issue of the article [Annual Inventory2022 Multiple Myeloma Progression Summary (Part I)-Expert Voice], we have selected and summarized the relevant content of 2 MM expert interviews/reviews in 2022, and this issue of "Annual Inventory" selects the latest research progress in the MM field in 2022, click the article to read the original article
.
IMS 2022Inventory of the therapeutic progress of bispecific antibodies in RRMM
22022 EHA Express | Preliminary results of the new BCMA/CD3 bispecific antibody - WVT078 in the treatment of R/R MM announced!
3The 2022 ASCO hit | live MagnetisMM-3 test data update! Elranatamab has a manageable safety profile in RRMM patients!
4Targeting BCMA bispecific antibody Teclistamab for the treatment of relapsed/refractory multiple myeloma with new progress
5FDA updated | approved TecListAMAB-CQYV for the treatment of relapsed or refractory multiple myeloma
1
IMS 2022 Express | Belantamab Mafodotin real-world data analysis results! The "new star" of RRMM backline therapy
IMS 2022 Express | BCMA CAR-T Cell Therapy RRMM Real-World Study Data Released! The efficacy and safety are good, and the toxicity of elderly patients does not increase!
22022 ASCO ExpressCART-ddBCMA has outstanding efficacy in the treatment of relapsed or refractory multiple myeloma
3The 2022 ASCO hit | live GPRC5D CAR-T cell therapy for a phase I, open-label, single-arm study in patients with RRMM
4Long-term efficacy and safety of BCMA CAR-T and CD19 CAR-T in the treatment of multiple myeloma
5BCMA-targeted CAR-T therapy still has a good efficacy and safety profile in patients with RRMM who have been exposed to BCMA-targeted drugs
6FDA Update | Approved ciltacabtagene autoleucel for patients with relapsed or refractory multiple myeloma
New direction of first-line treatment of NDMM patients: CD38 monoclonal antibody helps deep remission, and the combination of four drugs will become a trend
2Treatment of relapsed and refractory multiple myeloma: CD38 monoclonal antibody provides full benefit, and new drugs bring more options
3Elotuzumab in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis results from the ELOQUENT-3 phase II trial
4Safety and efficacy of Elotuzumab in combination with carfilzomib, lenalidomide and dexamethasone in the treatment of newly diagnosed multiple myeloma
52022 ASH | Prof.
Wu Mina: Rapid progress of NDMM treatment suitable for transplantation and unsuitable for transplantation
IMS 2022 ExpressThe new oral drug Mezigdomide combined with dexamethasone and bortezomib/carfilzomib in the treatment of RRMM has promising prospects
2IMS 2022 ExpressThe prospect is promising! Sotatercept holds promise to simultaneously treat anemia and bone disease in patients with multiple myeloma
3IMS 2022 ExpressNew Method! Novel targeted BCMA lipid nanoparticles for multiple myeloma treatment
4IMS 2022 For the first time, it was demonstrated that the treatment of PFS with prolonged KRd after MM autotransplantation was superior to lenalidomide monotherapy
5Does the new oral dual regimen lead to better outcomes for patients with RRMM?
6Research Express! Iberdomide in combination with dexamethasone in the treatment of advanced R/R MM is a new progress
Research progress of ASCT pretreatment protocol for MM patients in IMS 2022 ExpressMM
2IMS 2022 ExpressIn the era of new drugs, HSCT after the first remission may not be suitable for patients with multiple myeloma
3IMS 2022 Voice of China | Professor An Gang's team: Advances in induction therapy for multiple myeloma and autologous hematopoietic stem cell transplantation
4The 2022 ASCO hit | live Efficacy of RVd ± ASCT in combination with lenalidomide maintenance therapy in NDMM
5Quality of life in patients with multiple myeloma can return to normal population standards 1 year after ASCT
6ASCT is a safe and effective consolidation option for transplanted elderly NDMM patients
72022 EBMT Voice of China | Salvage ASCT is a cost-effective treatment option for patients with multiple myeloma who relapse after ASCT
82022 EBMT | In the era of new drugs, ASCT still plays an important role in patients with multiple myeloma
92022 EBMT | Tandem ASCT improves outcomes in patients with multiple myeloma
102022 EBMT Voice of China | Extended cyclophosphamide infusion is more effective as a stem cell mobilization regimen for NDMM patients: a retrospective, single-center study
NEW PROGRESS! CTC of more than 0.
07% is a useful predictor of prognosis in patients with multiple myeloma
Predictors of early mortality in multiple myeloma
3IMS 2022 Voice of China | 1q21 acquisition is an independent poor prognostic factor in patients with newly diagnosed multiple myeloma
4IMS 2022Multiple myeloma t(11; 14) Effects on treatment response and survival
5IMS 2022 Voice of ChinaThe research results of Professor Zhou Fan's team in the stratification of multiple myeloma biomarkers and prognosis
6IMS 2022 ExpressMRD Drive to Stop Multiple Myeloma Maintenance Therapy
7The simple new prognostic stratification system can effectively predict the prognosis of patients with newly diagnosed multiple myeloma
8R-ISS combined with 18F-FDG PET/CT parameters is expected to become a new risk stratification system for NDMM patients
9CD33 and CD13 in prognostic evaluation of multiple myeloma
10Value of PET/CT in the assessment of early response to treatment in patients with treatment-naïve multiple myeloma
11Patients with functional high-risk multiple myeloma have worse clinical outcomes
12Implications of persistent MRD negative and daratumab use in patients with NDMM: analysis of data from the MAIA and ALCYONE studies
13Real-world studies: treatment patterns and clinical outcomes in patients with MM with different cytogenetic risk stratifications
to treatment1
2022 ASH Voice of ChinaProfessor An Gang's team: research progress in multiple myeloma
2Multiple myeloma with kidney damage, how to solve the problem? | MM complication management
3How is MM bone disease managed? This work is increasingly important | MM complication management
Disclaimer: This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.
